3.2 Dental Analgesia Protocols, NSAIDs, Paracetamol & Opioid Stewardship

3.2 Dental Analgesia Protocols, NSAIDs, Paracetamol & Opioid Stewardship

Effective management of acute dental pain requires a thorough understanding of the inflammatory cascade, peripheral and central pain sensitization, and evidence-based pharmacotherapy aligned with Therapeutic Guidelines: Dental (eTG). Modern Australian dental practice prioritises non-opioid multimodal analgesia while restricting opioid use through strict antimicrobial and opioid stewardship principles.

---

Neurophysiology of Inflammatory Dental Pain

Dental pain arising from pulpal inflammation, periapical periodontitis, or surgical trauma is predominantly inflammatory nociceptive pain. Tissue injury triggers the release of membrane phospholipids, which are converted by phospholipase $A_2$ into arachidonic acid.

+---------------------------------------------------------------------------------------------------+
|                                 INFLAMMATORY PAIN CASCADE                                         |
|                                                                                                   |
|  Cell Membrane Phospholipids  ==[Phospholipase A2]==>  Arachidonic Acid                           |
|                                                                ||                                 |
|                                                    +[COX-1 / COX-2 Enzymes]+                      |
|                                                                ||                                 |
|                                                                /                                  |
|                                                  Prostaglandins (PGE2, PGI2)                      |
|                                                                ||                                 |
|                                                                /                                  |
|                                         Sensitization of Peripheral Nociceptors                   |
+---------------------------------------------------------------------------------------------------+

Prostaglandin $E_2$ ($PGE_2$) and Prostacyclin ($PGI_2$) sensitise peripheral free nerve endings ($A\delta$ and $C$ nociceptors) to chemical mediators such as bradykinin, histamine, and substance P, lowering the activation threshold for pain impulses transmitted to the central nervous system.

---

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

NSAIDs act by competitively inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby blocking the synthesis of pro-inflammatory prostaglandins.

• COX-1 Enzyme: Constitutively expressed in stomach mucosa, renal parenchyma, and platelets. Mediates gastric cytoprotection (via $PGE_2$), renal blood flow autoregulation, and platelet aggregation (via Thromboxane $A_2$).
• COX-2 Enzyme: Inducible isoform expressed predominantly at sites of tissue inflammation, pain, and cellular injury.

Non-Selective vs. COX-2 Selective NSAIDs

Primary Indications in Dental Practice

NSAIDs represent the first-line pharmacological agent for acute dental pain (e.g., pulpitis, post-extraction pain, surgical endodontic pain) because they target the primary peripheral inflammatory cause of nociception.

---

Paracetamol (Acetaminophen) Pharmacokinetics & Synergy

Paracetamol is an effective analgesic and antipyretic with weak peripheral anti-inflammatory action. Its precise mechanism involves central inhibition of prostaglandin synthesis, action on central serotonergic pathways, and interaction with the endocannabinoid system ($AM404$ active metabolite).

Adult Dosing Guidelines (eTG Dental)

• Standard Adult Dose: 500 mg to 1000 mg orally every 4 to 6 hours as required.
• Maximum Daily Limit: 4000 mg (4 g) in 24 hours for adults $>50\text{ kg}$.
• Hepatic Compromise / Chronic Alcoholism Limit: Capped at 2000 mg (2 g) in 24 hours to avoid accumulation of $N$-acetyl-$p$-benzoquinone imine ($NAPQI$), the toxic metabolite responsible for acute hepatic necrosis.

The Multimodal Synergistic Protocol

Clinical trials consistently demonstrate that combining a non-selective NSAID with Paracetamol produces superior pain relief than either agent alone, achieving an efficacy superior to standard oral opioid regimens (e.g., Codeine 60 mg or Oxycodone 5 mg).

MULTIMODAL DENTAL ANALGESIC REGIMEN:
-------------------------------------------------------------------------------------
Take TOGETHER every 6 hours:
  -> Ibuprofen 400 mg ORALLY
  -> Paracetamol 1000 mg ORALLY
-------------------------------------------------------------------------------------
Clinical Benefit: Dual peripheral (NSAID) and central (Paracetamol) pain inhibition
without increasing opioid-related adverse effects.

---

Stepped Dental Analgesia Protocols (Therapeutic Guidelines: Dental)

Australian dental practice follows a clear stepped protocol tailored to severity of expected or presenting pain:

+---------------------------------------------------------------------------------------------------+
|                                 STEPPED DENTAL ANALGESIC LADDER                                   |
|                                                                                                   |
|  STEP 1: Mild Pain        =======>  Paracetamol 1000 mg q6h OR Ibuprofen 400 mg q6h               |
|                                                                                                   |
|  STEP 2: Moderate Pain    =======>  Paracetamol 1000 mg PLUS Ibuprofen 400 mg TOGETHER q6h       |
|                                                                                                   |
|  STEP 3: Severe Pain      =======>  Paracetamol 1000 mg + Ibuprofen 400 mg q6h                   |
|                                     PLUS Short-Course Oxycodone 5 mg q6h (Max 2-3 days)           |
+---------------------------------------------------------------------------------------------------+

Summary Table of Analgesic Protocols

---

Contraindications, Precautions & Organ System Toxicity

NSAID Organ Toxicity Profile

1. Gastrointestinal Toxicity: Inhibition of COX-1 reduces protective gastric mucosal mucus and bicarbonate secretion. Risk factors include age $>65$, history of peptic ulcer disease, concurrent systemic corticosteroid use, and concomitant anticoagulant therapy.
2. Renal Impairment: Prostaglandins ($PGE_2$, $PGI_2$) maintain renal arteriolar vasodilation. NSAID administration in patients with compromised volume status or pre-existing renal disease can cause acute kidney injury (AKI) via afferent arteriolar constriction. Contraindicated if $\text{eGFR} < 30\text{ mL/min/1.73 m}^2$.
3. Cardiovascular Disease: Non-selective NSAIDs (except Naproxen) and COX-2 inhibitors impair endothelial $PGI_2$ production while sparing platelet $TXA_2$, promoting thrombosis. Contraindicated in severe heart failure (NYHA Class III/IV) and recent coronary artery bypass graft (CABG) surgery.
4. Pregnancy Considerations: NSAIDs are strictly contraindicated in the third trimester due to premature closure of the fetal ductus arteriosus and inhibition of uterine contractions leading to delayed labor.
5. Aspirin-Exacerbated Respiratory Disease (AERD / Samter's Triad): Triad of asthma, nasal polyposis, and aspirin/NSAID hypersensitivity. COX-1 inhibition shunts arachidonic acid metabolism down the 5-lipoxygenase pathway, driving massive cysteinyl leukotriene release and life-threatening bronchospasm.

---

Opioid Stewardship in Australian Dental Practice

In February 2018, the Therapeutic Goods Administration (TGA) rescheduled all over-the-counter codeine combination analgesics to Schedule 4 (Prescription Only) due to growing rates of misuse, dependence, and organ toxicity.

Pharmacogenomics of Codeine

Codeine is a prodrug requiring bioactivation to morphine via the hepatic enzyme CYP2D6.

• Poor Metabolisers (~6-10% of Caucasians): Possess non-functional CYP2D6 alleles and experience negligible analgesia.
• Ultra-Rapid Metabolisers (~1-7% of population, higher in North African and Middle Eastern ethnicities): Possess gene duplications resulting in rapid conversion to morphine, predisposing patients to potentially fatal respiratory depression even at standard doses.

Australian Guidelines on Dental Opioid Prescribing

• Opioids must never be prescribed as routine first-line therapy for dental pain.
• Indications are restricted to acute, severe pain refractory to maximal doses of Paracetamol and NSAIDs, or where NSAIDs are absolute contraindications.
• Prescription quantity must be limited to no more than 2 to 3 days supply (maximum 8–10 capsules/tablets of immediate-release Oxycodone 5 mg).
• Modified-release (sustained-release) opioid preparations are strictly prohibited for acute dental pain management.